{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T17:40:33Z","timestamp":1791481233048,"version":"4.3.4"},"reference-count":33,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","nmcd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nutrition, Metabolism and Cardiovascular Diseases"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.numecd.2022.07.002","type":"journal-article","created":{"date-parts":[[2022,7,19]],"date-time":"2022-07-19T02:12:06Z","timestamp":1658196726000},"page":"2451-2458","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Cardio-renal interaction - Clinical trials update 2022"],"prefix":"10.1016","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9666-2209","authenticated-orcid":false,"given":"Michael","family":"Kunz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"G\u00f6tzinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Insa","family":"Emrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7688-4576","authenticated-orcid":false,"given":"Vedat","family":"Schwenger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"B\u00f6hm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4425-549X","authenticated-orcid":false,"given":"Felix","family":"Mahfoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.numecd.2022.07.002_bib1","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0140-6736(20)30045-3","article-title":"Global, regional, and national burden of chronic kidney disease, 1990\u20132017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"395","author":"Bikbov","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.numecd.2022.07.002_bib2","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1016\/S0140-6736(17)30788-2","article-title":"Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy","volume":"390","author":"Levin","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.numecd.2022.07.002_bib3","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1056\/NEJMoa041031","article-title":"Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization","volume":"351","author":"Go","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.numecd.2022.07.002_bib4","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.numecd.2022.07.002_bib5","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1001\/jama.286.4.421","article-title":"Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals","volume":"286","author":"Gerstein","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.numecd.2022.07.002_bib6","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1001\/jama.2015.10081","article-title":"Effect of finerenone on albuminuria in patients with diabetic nephropathy","volume":"314","author":"Bakris","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.numecd.2022.07.002_bib7","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jacc.2021.04.079","article-title":"Finerenone reduces new-onset atrial fibrillation in patients with chronic kidney disease and type 2 diabetes","volume":"78","author":"Filippatos","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.numecd.2022.07.002_bib8","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.numecd.2022.07.002_bib9","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis","volume":"43","author":"Agarwal","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.numecd.2022.07.002_bib10","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1093\/eurheartj\/ehw132","article-title":"A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and\/or chronic kidney disease","volume":"37","author":"Filippatos","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.numecd.2022.07.002_bib11","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.numecd.2022.07.002_bib12","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.numecd.2022.07.002_bib13","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1093\/eurheartj\/ehab094","article-title":"Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD randomized controlled trial","volume":"42","author":"Heerspink","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.numecd.2022.07.002_bib14","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1161\/CIRCULATIONAHA.120.050391","article-title":"Efficacy of dapagliflozin on renal function and outcomes in patients with heart failure with reduced ejection fraction: results of DAPA-HF","author":"Jhund","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.numecd.2022.07.002_bib15","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1161\/CIRCULATIONAHA.120.051685","article-title":"Cardiac and kidney benefits of empagliflozin in heart failure across the spectrum of kidney function","volume":"143","author":"Zannad","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.numecd.2022.07.002_bib16","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/j.jacc.2022.01.029","article-title":"Mineralocorticoid receptor antagonists and empagliflozin in patients with heart failure and preserved ejection fraction","volume":"79","author":"Ferreira","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.numecd.2022.07.002_bib17","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/s41591-021-01659-1","article-title":"The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial","volume":"28","author":"Voors","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.numecd.2022.07.002_bib18","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/s41591-021-01659-1","article-title":"The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial","volume":"28","author":"Voors","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.numecd.2022.07.002_bib19","unstructured":"Jardiance\u00ae (empagliflozin) Phase III EMPA-KIDNEY trial will stop early due to clear positive efficacy in people with chronic kidney disease [n.d]."},{"key":"10.1016\/j.numecd.2022.07.002_bib20","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1161\/HYPERTENSIONAHA.110.161505","article-title":"Chlorthalidone reduces cardiovascular events compared with hydrochlorothiazide","volume":"57","author":"Dorsch","year":"2011","journal-title":"Hypertension"},{"key":"10.1016\/j.numecd.2022.07.002_bib21","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1161\/01.HYP.0000103632.19915.0E","article-title":"Hydrochlorothiazide versus chlorthalidone: evidence supporting their interchangeability","volume":"43","author":"Carter","year":"2004","journal-title":"Hypertension"},{"key":"10.1016\/j.numecd.2022.07.002_bib22","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","article-title":"ESC\/ESH Guidelines for the management of arterial hypertension","volume":"39","author":"Williams","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.numecd.2022.07.002_bib23","first-page":"E13","article-title":"ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American college of cardiology\/American heart association task force on clinical Pr","volume":"71","author":"Whelton","year":"2017","journal-title":"Hypertension"},{"key":"10.1016\/j.numecd.2022.07.002_bib24","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa2110730","article-title":"Chlorthalidone for hypertension in advanced chronic kidney disease","volume":"385","author":"Agarwal","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.numecd.2022.07.002_bib25","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.1093\/eurheartj\/ehv319","article-title":"ESC Guidelines for the management of infective endocarditis","volume":"36","author":"Habib","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.numecd.2022.07.002_bib26","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1136\/hrt.2005.063719","article-title":"Management of infective endocarditis","volume":"92","author":"Habib","year":"2006","journal-title":"Heart"},{"key":"10.1016\/j.numecd.2022.07.002_bib27","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1016\/j.jacc.2021.02.014","article-title":"Infective endocarditis in patients on chronic hemodialysis","volume":"77","author":"Peric\u00e0s","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.numecd.2022.07.002_bib28","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1161\/CIRCEP.112.974931","article-title":"Increased left ventricular mass as a predictor of sudden cardiac death","volume":"6","author":"Stevens","year":"2013","journal-title":"Circ Arrhythmia Electrophysiol"},{"key":"10.1016\/j.numecd.2022.07.002_bib29","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1681\/ASN.V1251079","article-title":"Left ventricular hypertrophy in the renal patient","volume":"12","author":"Middleton","year":"2001","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.numecd.2022.07.002_bib30","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ijcard.2017.03.002","article-title":"Hypertension, left ventricular hypertrophy, and sudden cardiac death","volume":"237","author":"Shenasa","year":"2017","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.numecd.2022.07.002_bib31","article-title":"Randomized trial of etelcalcetide for cardiac hypertrophy in hemodialysis","volume":"1616\u201325","author":"D\u00f6rr","year":"2021","journal-title":"Circ Res"},{"key":"10.1016\/j.numecd.2022.07.002_bib32","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1681\/ASN.2014101009","article-title":"Low vitamin D and high fibroblast growth factor 23 serum levels associate with infectious and cardiac deaths in the HEMO study","volume":"27","author":"Chonchol","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.numecd.2022.07.002_bib33","series-title":"Kerendia (finerenone)- European medicines agency","year":"2022"}],"container-title":["Nutrition, Metabolism and Cardiovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939475322002903?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939475322002903?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T16:21:42Z","timestamp":1760545302000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939475322002903"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":33,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["S0939475322002903"],"URL":"https:\/\/doi.org\/10.1016\/j.numecd.2022.07.002","relation":{},"ISSN":["0939-4753"],"issn-type":[{"value":"0939-4753","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cardio-renal interaction - Clinical trials update 2022","name":"articletitle","label":"Article Title"},{"value":"Nutrition, Metabolism and Cardiovascular Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.numecd.2022.07.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Italian Diabetes Society, the Italian Society for the Study of Atherosclerosis, the Italian Society of Human Nutrition and the Department of Clinical Medicine and Surgery, Federico II University. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}